Pfizer weighing sale of Hospira's pump business: Bloomberg
Reuters
Published Jan 13, 2016 11:06PM ET
Pfizer weighing sale of Hospira's pump business: Bloomberg
(Reuters) - Drugmaker Pfizer Inc (N:PFE) is thinking about selling hospital products maker Hospira's infusion pump business for about $2 billion, Bloomberg reported, citing people familiar with the matter.
Talks are said to be at an early stage, Bloomberg reported on Wednesday. (http://bloom.bg/1OQhp8A)
Pfizer closed its $15 billion acquisition of Hospira (N:HSP), which makes biosimilars and generic versions of injectable drugs, in September.
A Pfizer spokeswoman declined to comment.
Infusion pumps are computerized and are designed to deliver medications directly into patients' bloodstreams.
In November, Pfizer said it would buy Botox maker Allergan Plc (N:AGN) in a deal worth $160 billion, which would create the world's largest drugmaker.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.